IDH1 and cholangiocarcinoma: IDH1 mutations have been recurrently reported in low-grade glioma, glioblastoma multiforme (1), acute myeloid leukemia (AML) (2), cholangiocarcinoma (3), chondrosarcoma, and also melanoma (4,5).